In accordance with the FSA’s Disclosure and Transparency Rules, Ark Therapeutics Group plc (LSE: AKT) (‘Ark’ or the ‘Company’) confirms that as at the date of this announcement the Company’s issued share capital consists of 166,215,430 ordinary shares with voting rights.
